U.S. drugmaker Eli Lilly and Co. said the government-sponsored clinical trial of the company’s Covid-19 antibody treatment similar to one taken by U.S. President Donald Trump was paused because of a safety concern.
Shares of Voyager Therapeutics were down in trading after the company announced a clinical hold was placed on an experimental gene therapy treatment for Huntington’s disease before heading into the clinic.
Shares of Avenue Therapeutics plunged in trading after the company announced the U.S. Food and Drug Administration rejected the New Drug Application for intravenous tramadol over safety concerns.
The U.S. Food and Drug Administration issued an emergency use authorization for Abbott Laboratories’ lab-based Covid-19 antibody blood test.
Swedish Orphan Biovitrum (Sobi) announced that the rare disease drug maker’s phase 3 study of avatrombopag did not meet the clinical trial’s primary endpoint, sending the company’s shares sharply down.
Bristol Myers Squibb Co.’s cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial.
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).
Shares of Solid Biosciences skyrocketed in trading after the company announced the U.S. Food and Drug Administration lifted the clinical hold on the IGNITE DMD Phase I/II clinical trial.
Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.
Regeneron Pharmaceuticals Inc.’s experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients.
